SHERIDAN, WYOMING – November 10, 2024 – Johnson & Johnson MedTech, a global pioneer in orthopedic technologies, has showcased its advanced portfolio of products and data-driven solutions at the American Association of Hip and Knee Surgeons (AAHKS) 2024 Annual Meeting in Dallas. The company's latest innovations are set to redefine joint reconstruction procedures, enhancing surgical accuracy and patient outcomes.
Aldo Denti, Company Group Chairman, Orthopaedics, Johnson & Johnson MedTech, expressed his enthusiasm for the company's recent achievements, stating, “2024 has been a remarkable year of progress for Johnson & Johnson MedTech, marked by numerous clearances, launches, and strategic collaborations. Most notably, this was the single most successful year for major launches for the VELYS™ Enabling Tech portfolio.”
Solutions in Motion: A Holistic Approach to Joint Reconstruction
At the heart of Johnson & Johnson MedTech's offerings is the Solutions in Motion initiative, a comprehensive approach that integrates advanced surgical techniques, innovative implants, and data-driven technologies. This initiative is driven by the company's commitment to "driving meaningful improvements in patient outcomes while making surgeries more precise and efficient."
Key Innovations Unveiled at AAHKS 2024
VELYS™ Robotic-Assisted Solution for Unicompartmental Knee Arthroplasty (UKA): This groundbreaking technology utilizes CT-free technology to enable precise, surgeon-controlled implant placement and alignment for partial knee replacements. By preserving soft tissue, predicting joint stability, and supporting personalized knee function recovery, VELYS™ UKA offers a less invasive and more tailored approach to knee surgery.
WATSON EXTRACTION SYSTEM™: This innovative system simplifies femoral implant removal and revision, streamlining procedures and potentially avoiding more complex interventions. Its patented single-use, curved blades and reusable instruments enhance precision and efficiency, reducing surgery time and improving predictability.
VELYS™ Hip Navigation with CUPTIMIZE™ Advanced Hip-Spine Analysis & Guidance: This next-generation hip-spine analysis solution provides optimal orientation of the acetabular component, aiming to reduce the risk of edge loading and implant-implant impingement. Its sophisticated algorithm accounts for common risk factors and alerts surgeons to elevated dislocation risk, promoting greater implant stability and longevity.
Availability and Further Information
The VELYS™ UKA application and WATSON EXTRACTION SYSTEM™ are slated to be available by the end of the year, while CUPTIMIZE™ Hip-Spine Analysis is currently available in the United States. Attendees of the AAHKS meeting can explore these innovations and more at Booth #708 or online.
Johnson & Johnson MedTech: Committed to Transforming Orthopedic Care
Johnson & Johnson MedTech is dedicated to addressing the world's most pressing health challenges. In orthopedics, the company's mission is to keep people moving by leveraging its expertise in joint reconstruction, robotics, enabling technologies, spine, sports, trauma, and extremities. Its comprehensive orthopedics portfolio is designed to heal and restore movement for millions of patients worldwide.
About Johnson & Johnson
Johnson & Johnson is a global healthcare leader committed to building a world where diseases are prevented, treated, and cured. Through its expertise in innovative medicine and medtech, the company is uniquely positioned to deliver groundbreaking healthcare solutions that profoundly impact health for humanity.
Forward-Looking Statements
This press release contains forward-looking statements regarding the KINCISE™ 2 Surgical Automated System, VELYS™ Robotic-Assisted Solution, WATSON EXTRACTION SYSTEM™, and VELYS™ Hip Navigation with CUPTIMIZE™ Advanced Hip-Spine Analysis. Readers are cautioned not to rely on these statements, which are based on current expectations of future events. Actual results could vary materially due to various risks and uncertainties, including uncertainty of commercial success, challenges to patents, competition, manufacturing difficulties, product efficacy or safety concerns, changes to applicable laws and regulations, and trends toward health care cost containment.
Conclusion
Johnson & Johnson MedTech's groundbreaking innovations in joint reconstruction are poised to transform orthopedic care, offering surgeons and patients alike more precise, efficient, and personalized solutions. The company's commitment to advancing healthcare through cutting-edge technology is evident in its latest offerings, which promise to improve patient outcomes and keep people moving.